VanEck Vectors Biotech ETF Stock Forecast, Price & News

Wall Street analysts have given VanEck Vectors Biotech ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VanEck Vectors Biotech ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

VanEck Vectors Biotech ETF saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 32,700 shares, an increase of 144.0% from the July 29th total of 13,400 shares. Based on an average daily trading volume, of 16,600 shares, the days-to-cover ratio is currently 2.0 days.
View VanEck Vectors Biotech ETF's Short Interest.

VanEck Vectors Biotech ETF's stock was trading at $126.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BBH stock has increased by 70.9% and is now trading at $216.75.
View which stocks have been most impacted by COVID-19.

VanEck Vectors Biotech ETF announced an annual dividend on Friday, December 18th. Shareholders of record on Tuesday, December 22nd will be paid a dividend of $0.608 per share on Monday, December 28th. This represents a dividend yield of 0.35%. The ex-dividend date is Monday, December 21st. This is a positive change from VanEck Vectors Biotech ETF's previous annual dividend of $0.42.
View VanEck Vectors Biotech ETF's dividend history.

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and currently has a dividend yield of 0.28%.
View VanEck Vectors Biotech ETF's dividend history.

Some companies that are related to VanEck Vectors Biotech ETF include iShares MSCI Pacific ex Japan ETF (EPP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), PIMCO Corporate & Income Opportunity Fund (PTY), WisdomTree Emerging Markets High Dividend Fund (DEM), Hercules Capital (HTGC), Goldman Sachs BDC (GSBD), Royce Value Trust (RVT), Liberty All-Star Equity Fund (USA), Tri-Continental (TY), The Gabelli Equity Trust (GAB), iShares MSCI Australia ETF (EWA), Boulder Growth & Income Fund (BIF), Nuveen Nasdaq 100 Dynamic Overwrite Fund (QQQX) and Tekla Healthcare Investors (HQH).
View all of BBH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Biotech ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), (SNY), Intel (INTC), Micron Technology (MU), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), (MRNA) and Novavax (NVAX).

VanEck Vectors Biotech ETF trades on the NASDAQ under the ticker symbol "BBH."

VanEck Vectors Biotech ETF's stock is owned by many different retail and institutional investors. Top institutional investors include Goldman Sachs Group Inc. (4.10%), Morgan Stanley (2.21%), Morgan Stanley (2.19%), Royal Bank of Canada (1.89%), Bank of America Corp DE (1.12%) and Mogy Joel R Investment Counsel Inc. (1.03%).

BBH stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BHF RG Capital Inc., Goldman Sachs Group Inc., Bank of America Corp DE, Morgan Stanley, Morgan Stanley, Advisor Group Holdings Inc., and First National Bank of South Miami.

BBH stock was acquired by a variety of institutional investors in the last quarter, including Flow Traders U.S. LLC, Wealthspire Advisors LLC, Prudential PLC, Millennium Management LLC, Royal Bank of Canada, Mogy Joel R Investment Counsel Inc., Envestnet Asset Management Inc., and LPL Financial LLC.

Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BBH stock can currently be purchased for approximately $216.75.

VanEck Vectors Biotech ETF has a market capitalization of $627.92 million.